Setmelanotide | Buy Online | MC4R Obesity Guide

The patient was 16 years old and weighed 338 pounds. She'd been hungry every waking hour of her life—not the ordinary hunger that reminds you to eat lunch, but an unrelenting, overwhelming drive to consume that no amount of willpower could override. Her physicians had tried every intervention available. Nothing moved the needle. Then she enrolled in a Phase 3 trial of a synthetic cyclic peptide called setmelanotide, and within a year she had lost 68 pounds—roughly 20% of her body weight—and, for the first time, described her hunger as *normal*.

That case, reported in the 2021 *New England Journal of Medicine* trial by Clément et al., captured what makes setmelanotide genuinely different from every other weight-management compound in development. It doesn't work by suppressing appetite through serotonin pathways or slowing gastric emptying through GLP-1. It targets the exact molecular bottleneck that drives hyperphagia in specific genetic obesity syndromes—the melanocortin-4 receptor (MC4R) and the signaling cascade upstream of it.

For researchers studying the hypothalamic control of energy balance, setmelanotide is among the most mechanistically precise tools available. This guide covers everything: its origin, structure, mechanism, clinical evidence, dosing frameworks, safety profile, and how it compares to GLP-1 agonists and other metabolic peptides.

---

The Discovery: Finding the Lock Before Building the Key

The story of setmelanotide starts not with the peptide itself, but with a series of devastating natural experiments in human genetics.

In 1997, a British research team led by Sadaf Farooqi and Stephen O'Rahilly at the University of Cambridge identified two severely obese children—cousins—who carried homozygous frameshift mutations in the gene encoding leptin. These children had essentially no functional leptin, the adipose-derived hormone that signals satiety to the hypothalamus. Both were massively obese before age 10 and consumed extraordinary quantities of food. When the researchers administered recombinant leptin, the children lost weight rapidly and hunger normalized.

That finding ignited a decade of work mapping the leptin-melanocortin pathway in precise molecular detail. Leptin, it turned out, acts on neurons in the arcuate nucleus (ARC) of the hypothalamus that express pro-opiomelanocortin (POMC). When leptin binds its receptor on POMC neurons, these cells produce α-melanocyte-stimulating hormone (α-MSH), which then travels to the paraventricular nucleus (PVN) and activates MC4R. MC4R activation suppresses food intake and increases energy expenditure. It's a beautifully simple signaling relay—and every node in this chain can be broken by rare mutations.

By 2010, researchers had catalogued mutations in POMC, PCSK1 (which processes POMC into α-MSH), LEPR (leptin receptor), MC4R, and a scaffolding protein called SH2B1. Each mutation produced a similar phenotype: hyperphagia beginning in early childhood, severe obesity, and metabolic dysregulation. Collectively these syndromes affect an estimated 1 in 1,000 to 1 in 3,000 individuals, making them far more common than many physicians realize.

Rhythm Pharmaceuticals (later acquired by Ultragenyx) recognized that if the bottleneck in these syndromes was insufficient MC4R activation, then a potent, selective MC4R agonist could restore the signal pharmacologically—regardless of where upstream in the pathway the genetic lesion occurred. The compound they developed, setmelanotide (formerly RM-493), is a cyclic octapeptide designed to bind MC4R with high affinity and activate it with precisely calibrated efficacy.

The FDA granted setmelanotide Breakthrough Therapy Designation in 2018 and approved it under the brand name Imcivree in November 2020—the first approved treatment specifically for obesity caused by POMC, PCSK1, or LEPR deficiency in adults and pediatric patients six years and older.

---

Chemical Identity: An Engineered Cyclic Octapeptide

Setmelanotide's full chemical name is cyclo-[β-Ala-His-D-Phe-Arg-Trp-Glu]-NH₂, and that structural description encodes most of what makes it pharmacologically interesting.

Molecular formula: C₄₉H₆₈N₁₈O₉

Molecular weight: 1,117.2 Da

CAS number: 920014-72-8

Physical form: White to off-white lyophilized powder

Solubility: Highly water-soluble; reconstitutes readily in aqueous solutions

Stability: Stable at 2–8°C when lyophilized; solutions should be used within 24 hours or stored per manufacturer specifications

The cyclic architecture is the compound's most important structural feature. Unlike linear peptides, which are vulnerable to rapid proteolytic degradation, the lactam bridge between the β-alanine and glutamic acid residues creates a conformationally constrained ring that resists peptidase cleavage. This rigidity also pre-organizes the pharmacophore—the His-D-Phe-Arg-Trp core that makes direct contact with MC4R's binding pocket—into the bioactive conformation, dramatically improving receptor affinity compared to linear analogs.

The D-phenylalanine at position 3 deserves special mention. Substituting D-Phe for the natural L-Phe found in α-MSH increases both receptor selectivity and metabolic stability. It's a classic medicinal chemistry trick that setmelanotide's designers borrowed from earlier melanocortin research, including work on Melanotan II, a non-selective melanocortin agonist that activates MC1R, MC3R, MC4R, and MC5R simultaneously. Setmelanotide's selectivity for MC4R over other melanocortin receptor subtypes is substantially better—a critical distinction for safety, since MC1R activation drives skin pigmentation and MC2R activation affects adrenal steroidogenesis.

In the clinical formulation, setmelanotide is supplied as a 10 mg/mL solution for subcutaneous injection. Its half-life is approximately 11 hours after subcutaneous administration, supporting once-daily dosing. Bioavailability via subcutaneous injection is high, and peak plasma concentrations (Cmax) are reached within 6–8 hours post-injection.

---

Mechanism of Action: Fixing the Broken Thermostat

Primary Mechanism: MC4R Agonism in the Hypothalamic Energy Circuit

Understanding setmelanotide's mechanism requires a brief tour of the leptin-melanocortin energy balance circuit, because the peptide functions as a molecular bypass for every defect upstream of MC4R.

Under normal physiological conditions, adipose tissue secretes leptin in proportion to fat mass. Leptin crosses the blood-brain barrier and binds LepR on POMC neurons in the arcuate nucleus. This binding triggers a JAK2-STAT3 signaling cascade that drives transcription of the *POMC* gene. The POMC precursor protein is processed by PCSK1 (prohormone convertase 1/3) and PCSK2 into several bioactive fragments, including α-MSH (the endogenous MC4R agonist) and β-MSH.

α-MSH is released from POMC neuron axon terminals and travels to second-order neurons—particularly those in the paraventricular nucleus of the hypothalamus—where it binds MC4R. MC4R is a Gs-coupled GPCR: when α-MSH binds, the receptor activates adenylyl cyclase, raises intracellular cAMP, and activates PKA. The downstream effect is a reduction in food-seeking behavior and an increase in sympathetic nervous system tone—which translates to higher resting energy expenditure.

Simultaneously, a competing population of ARC neurons—AgRP/NPY neurons—releases agouti-related protein (AgRP), an endogenous inverse agonist at MC4R that constitutively suppresses receptor signaling. The balance between α-MSH and AgRP at MC4R is the molecular rheostat controlling hunger.

In patients with POMC, PCSK1, or LEPR deficiency, this system is broken at different points:

Setmelanotide bypasses all three defects. It's a synthetic, direct MC4R agonist—it activates the receptor without requiring any upstream signaling. The broken thermostat gets a direct power connection.

Key insight: Setmelanotide's mechanism means it works regardless of *where* the genetic lesion is, as long as MC4R itself is functional. This is why a single compound can treat three genetically distinct syndromes.

Secondary Pathways: Beyond Appetite Suppression

MC4R activation does more than reduce hunger. Through its Gs-cAMP-PKA axis, activated MC4R in the PVN increases sympathetic outflow to adipose tissue, promoting thermogenesis and lipolysis. This partially explains why setmelanotide-treated patients lose more weight than would be predicted from caloric restriction alone.

MC4R is also expressed in the dorsal vagal complex and nucleus tractus solitarius in the brainstem, where it modulates gastrointestinal motility and the gut-brain satiety relay. Some researchers believe MC4R activation in these nuclei contributes to the prolonged post-meal satiety signals observed in setmelanotide-treated patients.

There's also emerging evidence that MC4R signaling in the lateral hypothalamic area (LHA) influences reward-based eating. Several preclinical studies show that melanocortin agonism reduces the motivational drive to seek highly palatable food—not just the hedonic experience of eating, but the wanting. This distinction matters clinically: patients treated with setmelanotide report that food is less *compelling*, not just less enjoyable.

Systemic vs. Local Effects: Why Route Matters

Setmelanotide is administered subcutaneously in all approved protocols, and this route is intentional. The peptide must reach the CNS (via circumventricular organs and blood-brain barrier transport) to exert its primary anorectic effects. Intravenous administration produces similar efficacy but with higher Cmax and more pronounced early-phase side effects, particularly nausea. Oral administration is not viable—the cyclic structure, while more stable than linear peptides, is still degraded in the GI tract before reaching therapeutic plasma concentrations.

The 11-hour half-life means once-daily subcutaneous injection produces relatively stable plasma concentrations across the 24-hour dosing interval, avoiding the sharp peaks and troughs that contribute to side effects with some peptide therapies.

---

The Evidence Base: What the Clinical Trials Actually Show

POMC and PCSK1 Deficiency: The Phase 3 Pivotal Trial

The 2021 Clément et al. NEJM trial is the definitive evidence for setmelanotide in POMC/PCSK1 deficiency. This was a Phase 3, randomized, double-blind, placebo-controlled withdrawal study enrolling 10 patients with POMC deficiency and 11 with PCSK1 deficiency.

All patients received setmelanotide for 52 weeks, followed by an 8-week randomized withdrawal period where half continued the drug and half switched to placebo.

Key findings:

"The degree of weight loss achieved with setmelanotide in these patients surpasses what is seen with any currently available anti-obesity medication in the general population." — Clément et al., NEJM 2021

LEPR Deficiency: A Harder Population to Treat

Leptin receptor deficiency presents a more complex clinical picture than POMC deficiency because LepR is expressed on multiple cell types beyond POMC neurons—including immune cells, reproductive tissues, and peripheral metabolic organs. Setmelanotide can only restore the *anorectic* arm of leptin signaling, not the full receptor's pleotropic effects.

The Haws et al. 2020 Obesity trial enrolled 11 patients with confirmed biallelic LEPR mutations. After 52 weeks at doses titrated from 1–3 mg/day:

The response rate is lower than in POMC deficiency, which makes biological sense. LEPR deficiency disrupts the entire leptin signaling cascade, including immune regulation and pubertal development—effects that setmelanotide's MC4R agonism cannot address.

Bardet-Biedl Syndrome: Expanding the Indication

Bardet-Biedl syndrome (BBS) is a rare ciliopathy—a disorder of primary cilia—that causes obesity partly through disrupted melanocortin signaling. BBS proteins are required for proper trafficking of MCHR1 and MC4R to the primary cilium, where these receptors are thought to transduce hypothalamic energy signals.

The 2022 Clément et al. Nature Medicine trial (the DESTINY trial) enrolled 38 patients with genetically confirmed BBS in a Phase 3 randomized withdrawal design. After 52 weeks:

This trial was pivotal in securing the FDA's expanded approval for BBS in June 2022—making setmelanotide the first drug specifically approved for this syndrome.

Prader-Willi Syndrome and Emerging Applications

Prader-Willi syndrome (PWS) is another hyperphagia-dominant genetic obesity syndrome, caused by loss of paternally-expressed genes on chromosome 15q11–13. The MC4R pathway is implicated, but PWS involves additional hypothalamic dysregulation including growth hormone deficiency and oxytocin pathway disruption.

A 2023 Phase 2 trial in 12 patients with PWS showed statistically significant hunger reduction and modest but measurable weight loss (mean −5.8% at 52 weeks). The response was smaller than in POMC or BBS patients, consistent with PWS's more complex pathophysiology. Rhythm Pharmaceuticals has ongoing Phase 3 trials in PWS as of 2024–2025.

SH2B1 deficiency, a recently characterized genetic obesity syndrome caused by haploinsufficiency of a leptin signaling scaffold protein, showed a 60% responder rate in the Eneli et al. 2020 trial—suggesting that setmelanotide's target population may expand further as genetic sequencing identifies new MC4R pathway lesions.

---

Complete Dosing Guide: Protocols from Clinical Research

All dosing information below reflects protocols used in clinical trials and the FDA-approved prescribing information for Imcivree. This is provided for research documentation purposes.

Beginner Protocol (Conservative Titration)

The approved protocol begins with a low starting dose and titrates upward based on response and tolerability. The primary side effect limiting rapid escalation is nausea, which is dose-dependent and typically resolves within 1–2 weeks as tolerance develops.

Starting dose: 0.5 mg/day subcutaneous injection, once daily, in the morning

Titration: Increase by 0.5 mg every 2 weeks if tolerated

Target dose: 1.0–2.0 mg/day for most patients

The morning injection timing is not arbitrary—it aligns peak plasma concentrations (reached at ~6–8 hours post-injection) with the late afternoon/evening period when hunger-driven eating behavior is typically most problematic.

Standard Protocol (Approved Clinical Dosing)

Maximum approved dose: 3.0 mg/day in adults

Reconstitution notes: The clinical formulation is provided as a ready-to-inject 10 mg/mL solution. Research-grade lyophilized setmelanotide is typically reconstituted in bacteriostatic water (BAC water) to achieve a working concentration of 2–5 mg/mL. Use 1 mL BAC water per 2 mg peptide for a 2 mg/mL solution. Inject BAC water slowly down the vial wall; do not shake. Allow 5–10 minutes for complete dissolution.

Storage: Lyophilized powder: −20°C, protected from light, up to 24 months. Reconstituted solution: 2–8°C, up to 28 days. Do not freeze reconstituted solution.

Advanced Protocol (Extended Research Dosing)

In the Phase 3 trials, a subset of patients at the 3.0 mg/day dose showed continued weight loss between weeks 52 and 104 without plateau—suggesting that unlike some anti-obesity agents, setmelanotide's efficacy may not wane with prolonged use. Long-term extension studies are ongoing.

For researchers studying dose-response relationships:

The injection site matters for pharmacokinetics. Abdominal subcutaneous tissue produces faster absorption than thigh or upper arm sites; rotating sites reduces local reactions.

---

Stacking Strategies: Mechanistic Combinations Worth Researching

Stack 1: Setmelanotide + Semaglutide — Complementary Anorectic Pathways

Rationale: Setmelanotide activates MC4R centrally; semaglutide activates GLP-1 receptors in the brainstem, vagal afferents, and hypothalamus. These are genuinely distinct pathways. Semaglutide's primary mechanism involves slowing gastric emptying and reducing postprandial glucagon—setmelanotide doesn't touch these mechanisms. In theory, combining them addresses both the hypothalamic hunger signal (via MC4R) and the peripheral satiety signal (via GLP-1R).

Preclinical support: A 2022 mouse study using MC4R agonism combined with GLP-1R agonism showed additive weight loss without additive nausea—suggesting the side effect profiles don't simply compound.

Practical caveat: This combination has not been formally tested in humans with genetic obesity syndromes. In the general obesity population, semaglutide alone produces 15–17% weight loss; whether adding setmelanotide meaningfully augments this in non-genetically-defined patients is unresolved.

Stack 2: Setmelanotide + Tesamorelin — Metabolic Recomposition

Rationale: Setmelanotide reduces fat mass through appetite suppression and increased sympathetic thermogenesis. Tesamorelin—a GHRH analog—increases GH pulsatility, which drives preferential visceral fat mobilization. The two compounds address different fat compartments through entirely different mechanisms: setmelanotide operates via the hypothalamic melanocortin system; tesamorelin operates via the GH-IGF-1 axis.

This combination is most relevant for research into hypothalamic obesity where both hyperphagia and GH deficiency coexist—a documented occurrence in patients with craniopharyngioma or hypothalamic damage.

Stack 3: Setmelanotide + MOTS-c — Mitochondrial Energy Expenditure Enhancement

Rationale: MOTS-c is a mitochondria-derived peptide that activates AMPK in skeletal muscle, improving insulin sensitivity and glucose metabolism. It complements setmelanotide's central appetite effects with peripheral metabolic improvements. In obese rodent models, MOTS-c alone reduces fat mass through metabolic reprogramming rather than appetite suppression. Combining the two theoretically addresses both energy intake (setmelanotide) and energy utilization (MOTS-c).

This is a speculative but mechanistically coherent research stack with no published human combination data as of 2025. Researchers interested in the complementary pathways should approach with appropriate preclinical validation.

---

Safety Deep Dive: What the Data Actually Shows

Common Side Effects (Frequency from Phase 3 Trials)

Injection site reactions are the most common adverse event, reported in approximately 22–34% of patients across trials. These are typically mild erythema, induration, or pruritus at the injection site that resolve within 24–48 hours. Rotating injection sites (abdomen, thigh, upper arm) reduces frequency.

Nausea occurs in approximately 15–27% of patients, almost always during dose titration. It's typically mild-to-moderate, transient (resolving within 1–2 weeks), and rarely leads to discontinuation. Taking the injection with food or adjusting injection timing can mitigate this.

Skin hyperpigmentation (spontaneous) is reported in approximately 10–18% of patients. This occurs because MC1R—while less sensitive to setmelanotide than MC4R—is still partially activated, especially at higher doses. The hyperpigmentation is diffuse rather than focal, reversible upon discontinuation, and cosmetically noticeable but not medically concerning in most cases.

Sexual adverse events: MC4R activation in the spinal cord and peripheral autonomic neurons can cause spontaneous erections in males (reported in ~4–8% of male trial participants) and increased sexual desire in both sexes. These effects were reported as adverse events in trials but are mechanistically predictable—MC4R in the spinal cord mediates erectile function, which is why compounds like PT-141 (bremelanotide), another melanocortin agonist, are studied for sexual dysfunction.

Nausea and vomiting (combined): ~20–30% during titration phase, <5% at stable maintenance dosing.

Fatigue and headache are reported at 5–10% frequency, typically early in treatment.

Rare and Theoretical Risks

Depression and suicidal ideation: The FDA prescribing information includes a warning about depression and suicidal ideation based on reports in the clinical program. The mechanism is unclear—MC4R is expressed in limbic circuits—but the absolute number of events was small. Patients with a history of major depression warrant closer monitoring.

Hypothalamic-pituitary axis effects: At very high doses, non-selective melanocortin activation could theoretically affect ACTH release (via MC2R on adrenal cells) or other pituitary functions. At approved doses, no clinically significant endocrine disruption has been documented.

Theoretical oncological concerns: Melanocortin signaling influences melanocyte activity. There are no reports of increased melanoma risk in setmelanotide trials, and the compound has lower MC1R activity than non-selective agonists like Melanotan II. However, long-term carcinogenicity data in humans extends only to the trial durations (up to ~5 years in extension studies). Patients with personal or family history of melanoma should discuss risk-benefit with a physician.

Immunogenicity: A small proportion of patients (~3%) develop anti-setmelanotide antibodies. In most cases this does not reduce efficacy, but monitoring is recommended in long-term use.

Contraindications and Precautions

---

Setmelanotide vs. Alternatives: Where It Fits in the Therapeutic Landscape

Setmelanotide occupies a unique niche. It's not competing with GLP-1 agonists for the general obesity market—it's the only precision therapy for specific genetic obesity syndromes. But researchers and clinicians need to understand how it compares to the broader toolkit.

The critical comparison is with leptin replacement therapy (metreleptin/Myalept), which is the only other approved treatment for a subset of genetic obesity syndromes:

This highlights a key principle: genetic testing determines which therapy is appropriate. Setmelanotide is useless in leptin deficiency (leptin replacement is needed); metreleptin is useless in LEPR deficiency (the receptor is broken); neither works in MC4R deficiency.

---

Where to Buy Setmelanotide for Research

Setmelanotide (Imcivree) is an FDA-approved prescription medication. In clinical settings, it's dispensed through specialty pharmacies under REMS (Risk Evaluation and Mitigation Strategy) requirements.

For research purposes, synthetic setmelanotide is available from select peptide research suppliers. When sourcing any research-grade peptide, purity verification is non-negotiable. Look for:

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

---

What's Coming Next: The Frontier of MC4R Research

Expanding Genetic Indications

As whole-exome sequencing becomes standard in obesity evaluation, the number of identified MC4R pathway lesions is growing. Rhythm Pharmaceuticals has an ongoing EMANATE basket trial enrolling patients with a growing list of genetic variants—including KSR2 deficiency, SIM1 haploinsufficiency, and ADCY3 loss-of-function mutations—all of which are hypothesized to impair melanocortin signaling. Early EMANATE data presented at ENDO 2023 showed meaningful weight loss in several of these genotypes.

MC4R heterozygous mutations are the most common cause of monogenic obesity, affecting ~1 in 200 individuals. The open question is whether setmelanotide can partially activate the remaining functional MC4R copy in these patients sufficiently to produce meaningful weight loss. A 2019 Kühnen et al. trial in 15 heterozygous patients showed dose-dependent weight loss, but the response was variable—suggesting that genetic context (which specific MC4R variant is present) determines pharmacological responsiveness.

Combination Therapy Trials

Rhythm Pharmaceuticals initiated a Phase 2 study in 2023 combining setmelanotide with setmelanotide + GIPR agonism in patients with hypothalamic obesity following craniopharyngioma surgery—a population with acquired, rather than congenital, melanocortin pathway disruption. Results are expected in 2025–2026.

Oral Formulation Development

The holy grail for any peptide therapy is oral bioavailability. Rhythm's medicinal chemistry team has published preliminary data on peptidomimetic MC4R agonists that incorporate non-natural amino acids and N-methylation to resist GI degradation. None have reached clinical trials yet, but the structural lessons from setmelanotide's cyclic architecture are informing these next-generation compounds.

MC4R in Non-Genetic Obesity

A provocative unresolved question: does functional MC4R deficiency—not from genetic mutation, but from downregulation of POMC neuron activity in diet-induced obesity—contribute to the maintenance of obesity in the broader population? Several rodent studies suggest that high-fat diet feeding suppresses POMC neuron activity, creating a *functional* melanocortin deficiency. If true, setmelanotide or related compounds might have a role in non-genetic obesity that hasn't been fully explored. The EMANATE basket trial is partly designed to answer this question in humans with variants of uncertain significance in MC4R pathway genes.

Biomarkers for Response Prediction

Currently, the best predictor of setmelanotide response is baseline hunger score—patients with higher pre-treatment hunger are more likely to respond. This makes sense mechanistically: if hyperphagia is the primary driver of obesity, reducing the hunger signal produces weight loss; if obesity has additional or alternative drivers, the response is muted. Researchers at the Broad Institute are working on a polygenic melanocortin pathway score that might predict response from a blood sample, potentially replacing the need for 12-week therapeutic trials before committing to long-term treatment.

---

Key Takeaways

---

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Related Articles on BuyPeptidesOnline.com